Drug intelligence / Profile preview

vedicetumab

Development stage: Unknown
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Vedicetumab is an experimental drug currently being investigated in a Phase II clinical study. It is being evaluated in combination with tislelizumab as a neoadjuvant sequential adjuvant therapy for locally advanced upper urinary tract urothelial carcinoma. Due to limited specific information, its precise mechanism of action, modality, and developer are not clearly established under this exact name.

Brand names: Aidexi
Other names: Edisil

Targets

α4β7 (Integrin alpha-4 beta-7 heterodimer)

Beyond the preview

Go deeper on vedicetumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vedicetumab.

Explore the full profile